TMCI - NASDAQ
Treace Medical Concepts, Inc.
$3.40
-5.6%Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
At a Glance
Live SnapshotTreace Medical Concepts, Inc. Management Team
Mr. Gaetano M. Guglielmino
Chief Commercial Officer
Compensation
$137,338
Mr. John T. Treace
Chief Executive Officer, Founder & Director
Compensation
$828,346
Mr. Mark L. Hair CPA
Chief Financial Officer
Compensation
$531,907
Mr. Daniel E. Owens
Chief Human Resources Officer
Mr. Taylor Erickson
Chief Information & Cybersecurity Officer
Dr. Sean F. Scanlan Ph.D.
Chief Innovation Officer
Compensation
$457,834
Mr. Scot M. Elder J.D.
Chief Legal & Compliance Officer and Corporate Secretary
Compensation
$565,557
Mr. Terry W. Lubben
Chief Operations & Supply Chain Officer
Ms. Shana Zink
Senior Vice President of Clinical Affairs & Reimbursement
Mr. Aaron J. Berutti
Senior Vice President of Sales
Compensation
$484,223
Treace Medical Concepts, Inc. Insider Positioning
During the last 12 months, insiders have purchased $894K and sold $24K worth of TMCI shares, resulting in $870K of net buying activity.
3 Months
319.3K
894.00K
0
0.00
+894K
+$894K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
33.4K
24.00K
-24K
-$24K
Top Buyers
Treace John T.
Director, 10 Percent Owner, Officer: Chief Executive Officer
$894K
Top Sellers
Scanlan Sean F.
Officer: Chief Innovation Officer
$24K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $870K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Sustained buying momentum: Consistent net buying over multiple quarters suggests insiders maintain conviction in the company's prospects. This is particularly meaningful if buying continued through market volatility.
SEC Filings
TMCI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 07, 2025 | April 07, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2024 | April 02, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2023 | May 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 04, 2022 | May 17, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.